Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Welcome :
IBI01 - Circulation
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Market Data
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
HIGHLIGHT CONTENT - Staging
27 August 2010

Belgian antibody firm Ablynx has completed its secondary public offering, raising €50 million through the sale of just under 6.7 million new shares at €7.50 each. An over-allotment option of up to 400,000 shares worth €3 million in total will be covered by lending shareholders selling...

 
Pfizer to bolster rare disease portfolio with FoldRx acquisition
02 September 2010
Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two ...
Relief for Dendreon on upcoming US Medicare coverage meeting on Provenge
02 September 2010
The US agency that runs Medicare – the Centers for Medicare and Medicaid Services (CMS) - has scheduled a 17 November advisory panel meeting to consider ...
Deal with Ono the first for Concordia's novel Ras inhibitor
02 September 2010
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which ...
Addex makes plans to move mGluR2 antagonist into clinical trials for Alzheimer's disease
02 September 2010
Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year. "We are currently in late-stage ...
 
Index appoints Johnson partner
02 September 2010
Index Ventures, the global high tech venture capitalist, has appointed Dr Kevin Johnson as a life sciences partner to enhance its push into developing asset-centric investment strategy. Dr Johnson, ...
New investor leads Celator's $20 million series D
02 September 2010
Celator Pharmaceuticals has raised $20 million in a series D round led by new investor Thomas, McNerney & Partners. Alex Zisson , a partner at the venture capital firm, will join Celator's ...
Scottish biotech companies combine
02 September 2010
Two Scottish university spin-out companies, ImmunoSolv and Grampian BioConsultants (GBC), have merged to combine their expertise in immunology and immuno-technology to avoid becoming a "one-trick ...
Henderson Morley files notice of administration
02 September 2010
The small UK biotechnology firm Henderson Morley has filed a notice of intention to call in the administrators following its failure to secure the divestment of its ICVT (Ionic Contra Viral Therapy) ...
 
ThromboGenics' microplasmin positive in second Phase III trial
02 September 2010
ThromboGenic's microplasmin met its primary endpoint – resolution of vitromacular adhesion (VMA) – in patients with the eye disease. The study results, presented at the American Society of Retina ...
Xeloda filed in Japan for additional gastric cancer use
02 September 2010
Roche's Japanese subsidiary, Chugai , has made an approval filing for Xeloda (capecitabine) for the treatment of advanced or refractory gastric cancer in patients who are not candidates for curative ...
Japan to subsidise Takeda's cell cultured flu vaccine R&D
02 September 2010
The Japanese government is to provide a multi-million dollar subsidy to the country's largest pharma company for the development of cell cultured vaccines for pandemic influenza. Following an ...
BMS/Pfizer's apixaban emerges as a strong anti-coagulation contender
01 September 2010
Bristol-Myers Squibb's apixaban beat aspirin (acetylsalicylic acid) for the prevention of venous thromboembolism (VTE) in patients at high-risk of atrial fibrillation (AF) who were unable to take ...
 
India throws rule book at 'superbug' scientists
02 September 2010
Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various ...
US appeals court upholds Evista patents through 2014, blocking Teva generic
02 September 2010
A federal appeals court has affirmed a lower court ruling that Lilly's method-of-use patents for its osteoporosis drug Evista (raloxifene) are valid until 2014, blocking an attempt by Teva ...
New Zealand expects savings following funding decision for Dr Reddy'squetiapine
02 September 2010
New Zealand expects to save NZ$24 million ($17.1 million) over the next five years following price reductions for certain antipsychotic drugs, said Pharmac , the country's pharmaceutical management ...
Czech agency identifies drugs facing December sunset clause
01 September 2010
SÚKL , the Czech State Institute for Drug Control, has issued a list of medicines that might be subject to a 31 December 2010 sunset clause that will invalidate their marketing authorisations based ...
 
PEOPLE
New appointment at King Pharmaceuticals King Pharmaceuticals (US) has appointed Jeffrey Bailey chief commercial officer. He will be ...
One Nucleus appoints new director One Nucleus, a UK-based not-for-profit membership organisation for international life science and ...
New COO at Millennium Laboratories Millennium Laboratories (US), a provider of therapeutic drug monitoring and education to physicians ...
>> More People News...

Asia Beat: Debate drags on as Taiwan gets its NHI house in order
01 September 2010
Ian Haydock
Taiwan's efforts to reform its financially struggling national health insurance (NHI) scheme go ...

ObamaCare: Here comes change
30 July 2010

President Barack Obama's commitment to health reform was unmistakeable in February 2009, when he ...

ObamaCare: World's largest pharma market to get bigger still
23 July 2010

Pharma companies stand to benefit from significant growth in their customer base. Other changes in ...

ObamaCare: The stuff of dreams
23 July 2010

Assessing the impact of the reform on pharma is a cost-benefit exercise. The industry will have to ...

MULTIMEDIA
Scrip's 2009 Review 06 January 2010

Get the Flash Player to see this player.

Private investment round-up: December 2009
06 January 2010
Simon Varcoe
The private investment market ended 2009 on a high, with 14 pharmaceutical and biotech companies ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Face-to-Face: Trophos - The French firm that hooked Actelion
23 July 2010
Simon Varcoe
Actelion this week acquired the option to buy private company Trophos, with the final decision ...

Test Supplements - 2
30 June 2010
Test Supplements - 2

EVENTS
01 January 2011
Scottsdale, Arizona
20 December 2011
Brussels, Belgium
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm